share_log

Morgan Stanley Downgrades Prelude Therapeutics to Underweight, Lowers Price Target to $4

Benzinga ·  Dec 19, 2023 22:33

Morgan Stanley analyst Jeffrey Hung downgrades Prelude Therapeutics (NASDAQ:PRLD) from Equal-Weight to Underweight and lowers the price target from $10 to $4.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment